Insulet (PODD) Misses Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq slides over 1% as Alphabet results revive AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Wedbush Raises Price Target on Insulet (PODD) Following 3Q
November 6, 2015 8:45 AM ESTWedbush reiterated an Outperform rating on Insulet Corporation (NASDAQ: PODD), and raised the price target to $44.00 (from $40.00), following the company's 3Q earnings report. The new managements team is successfully capturing a healthy number of new patients (almost 25% yr/yr) through improved marketing... More



